Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02583243 · ClinicalTrials.gov registry record
Project BEST: Buprenorphine Entry Into Substance Abuse Treatment
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 209
- Enrollment target
NCT02583243: Completed study, sponsored by Yale University.
NCT02583243 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 209 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02583243 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 209 participants
- Enrollment target
Study Summary
Project BEST is a clinical project funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to increase treatment to opiate dependent patients with mental illness in New Haven, CT and to prospectively follow everyone enrolled in buprenorphine care for as long as the individual takes buprenorphine to track the success of buprenorphine for the maintenance of opiate dependence.
Interventions
- DRUG Buprenorphine
- BEHAVIORAL MET/CBT based individualized counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-08 |
What the finished NCT02583243 record still lists
NCT02583243 is an observational study that tracks outcomes without assigning an intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Buprenorphine is the first listed.
NCT02583243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02583243 about?
NCT02583243 is a clinical study titled "Project BEST: Buprenorphine Entry Into Substance Abuse Treatment". Project BEST is a clinical project funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to increase treatment to opiate dependent patients with mental illness in New Haven, CT and to prospectively follow everyone enrolled in buprenorphine care for as long as the individua...
What is the current status of trial NCT02583243?
This trial is currently completed. The enrollment target is 209 participants. The study started on 2005-05. Estimated completion is 2008-08.
What interventions are being tested in trial NCT02583243?
The interventions under investigation include: Buprenorphine (DRUG), MET/CBT based individualized counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT02583243?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia